ARQT vs. SMMT

In the year-to-date period, ARQT achieves a -5.96% return, which is significantly lower than SMMT's 15.55% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Arcutis Biotherapeutics, Inc. (ARQT) and Summit Therapeutics Inc. (SMMT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current ARQT Sharpe Ratio is 1.25, which is comparable to the SMMT Sharpe Ratio of 1.40. The chart below compares the historical Sharpe Ratios of ARQT and SMMT, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither ARQT nor SMMT has paid dividends to shareholders.

The maximum ARQT drawdown since its inception was -95.02%, roughly equal to the maximum SMMT drawdown of -95.75%. Use the drawdown chart below to compare losses from any high point for ARQT and SMMT. For additional features, visit the drawdowns tool.

The current volatility for Arcutis Biotherapeutics, Inc. (ARQT) is 18.93%, while Summit Therapeutics Inc. (SMMT) has a volatility of 27.20%. This indicates that ARQT experiences smaller price fluctuations and is considered to be less risky than SMMT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Arcutis Biotherapeutics, Inc. and Summit Therapeutics Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.